Theravance Biopharma, Inc. · NASDAQ:TBPH
Theravance Biopharma — Corporate Update (April 2020)
12 slides from Theravance Biopharma's corporate update, Apr 9, 2020
Slide 1: TD-0903: Nebulized pan-JAKi for Acute Lung Injury Associated with COVID-19
THERAVANCE ® , the Cross/Star logo, and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies. All third party trademarks used herein are the property of their respective owners. © 2020 Theravance Biopharma. All rights reserved. TD - 0903: Nebuli
Slide 2: Forward looking statements
Forward looking statements Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, the company cautions investors th at any forward - looking statements or projections made by the company are subject to risks and uncertainties that may cause actual resul ts to
Slide 3: Lung selective JAK inhibitor targeted at cytokine storm
Lung selective JAK inhibitor targeted at cytokine storm 3 TD - 0903
Slide 4: Pan-JAK Inhibitor Designed Specifically for Lung Diseases
Pan - JAK Inhibitor Designed Specifically for Lung Diseases Leveraging >20 years of experience in design of novel respiratory drugs Respiratory experience ‣ Three commercial programs with GSK collaboration* (ANORO ELLIPTA, BREO ELLIPTA, TRELEGY ELLIPTA) ‣ Discovered and developed YUPELRI ® (revefena
Slide 5: Clinical course for patients who develop ALI and ARDS
5 26% of patients go to ICU 64% dyspneic 61% have ARDS 29% are HCPs 12% are hospitalized patients Clinical course for patients who develop ALI and ARDS Wang D et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus - Infected Pneumonia in Wuhan, Chi na. JAMA; Feb 202
Slide 6: Host Inflammatory Response Drives ALI and ARDS
Host Inflammatory Response to COVID - 19 Drives ALI and ARDS Adapted from Siddiqi HK, et al. J Heart Lung Transplant 2020 Mar 20. 6 6 Clinical symptoms Clinical signs Potential therapies Mild constitutional symptoms Fever >99.6 ° F Dry cough, diarrhea, headache Shortness of breath Hypoxia (PaO 2 /Fi
Slide 7: Inhaled pan-JAK inhibitor could suppress dysregulated immune response in the lung
Inhaled pan - JAK inhibitor could suppress dysregulated immune response (“cytokine storm”) in the lung Adapted from Channappanavar R, Perlman S. Seminars in Immunopathology 2017; 39:529 - 39. 7 Inflammatory Response to Pathogenic hCoV Infections CAUSES CONSEQUENCES OUTCOMES • Non - robust virus repl
Slide 8: Cytokine profile associated with disease severity
8 ▪ A cytokine profile resembling sHLH is associated with COVID - 19 disease severity, characterized by increased IL - 2, IL - 7, GCSF, IP - 10, MCP - 1, MIP1 - α and TNF - α ▪ A multicenter, randomized controlled trial of tocilizumab (IL - 6 receptor blockade, licensed for cytokine release syndrome
Slide 9: Pan-JAK inhibition: decrease signaling of multiple pro-inflammatory cytokines
Pan - JAK inhibition: decrease signaling of multiple pro - inflammatory cytokines associated with COVID - 19 Clark JD, et al. J Med Chem 2014; 57:5023 - 5038. 9 STAT - induced Inflammation α N UCLEUS STAT P STAT P STAT P STAT P STAT JAK β γ JAK JAK inhibitor γ c cytokines (IL - 2, IL - 4, IL - 7, IL
Slide 10: TD-0903: Potent, lung-selective inhaled pan-JAKi
BALF lymphocytes and relevant mediators inhibited by OA tool JAK inhibitor TR065925 Based on internal data on file TD - 0903: Potent, lung - selective inhaled pan - JAKi DESIGN: MAXIMAL ANTI - INFLAMMATORY ACTIVITY IN PULMONARY TISSUE WHILE MINIMIZING SYSTEMIC EXPOSURE ‣ High affinity for JAK1, JAK2
Slide 11: Nebulized delivery of an inhaled JAKi is optimal for hospital use
Hospitalized COVID - 19 patients with ALI have varying levels of ventilatory support Nebulized delivery of an inhaled JAKi is optimal for hospital use 11 Mechanical Ventilation High - Flow Nasal Cannulation Non - Invasive Ventilation Mask Oxygen
Slide 12: Our Mission
Apply lung selective JAK inhibition to fight cytokine storm in COVID - 19 Our Mission 12 Transform the treatment of serious diseases through the discovery, development, and commercialization of organ - selective medicines designed to maximize patient benefit while minimizing patient risk